Impact of PROphet Assay in Changing Physician’s Therapeutic Decision-Making for Checkpoint Immunotherapy in NSCLC (Non-Small Cell Lung Cancer)

• D. Gandara,
• J. Subramanian,
• E. Santos,
• I. Sela,
• Y. Elon,
• M. Harel,
• K. Mcgregor

Affiliations

D. Gandara

UC Davis, Sacramento, USA

J. Subramanian

Inova Schar Cancer Institute, Fairfax, USA

E. Santos

Florida Atlantic University, Boca Raton, USA

I. Sela

OncoHost, Binyamina, Israel

Y. Elon

OncoHost, Binyamina, Israel

M. Harel

OncoHost, Binyamina, Israel

K. Mcgregor

OncoHost, Cary, USA